Search

Displaying results 2591 - 2600 of 3733 in total
  1. Drug

    Gilteritinib

    go.drugbank.com/drugs/DB12141
    ApprovedInvestigational

    Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  2. Drug

    Secoisolariciresinol

    go.drugbank.com/drugs/DB12179
    Investigational

    Secoisolariciresinol has been used in trials studying the prevention of Breast Cancer.

    Categories: P-glycoprotein inhibitors
  3. Drug

    Gepirone

    go.drugbank.com/drugs/DB12184
    Approved

    Gepirone, an azapirone, is a pharmacologic analog of buspirone that acts selectively on the pre- and post-synaptic 5HT1A receptors. Although earlier clinical trials showed promising results for gepirone, its formulation as an immediate-r...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    Hormone receptor (HR) positive, especially estrogen receptor-positive, HER2-negative breast cancer is the most common subtype of metastatic breast cancer, resulting in more than 400,000 deaths annually

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    Bexagliflozin

    go.drugbank.com/drugs/DB12236
    ApprovedInvestigational

    Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge. SGLT2 is ...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    Fexinidazole

    go.drugbank.com/drugs/DB12265
    Approved

    Human African trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by T. brucei gambiense and T. brucei rhodesiense, remains a moderate risk (>1/10,000 inhabitants per year in endemic areas) despite focuss...

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Substrates
  7. Drug

    Epofolate

    go.drugbank.com/drugs/DB12266
    Investigational

    Epofolate (BMS-753493) is a folate conjugate of the epothilone analog BMS-748285 that was designed to selectively target folate receptor expressing cancer cells.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  8. Drug

    Brigatinib

    go.drugbank.com/drugs/DB12267
    ApprovedInvestigational

    Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  9. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-β plaques in the brain; similar to gantenerumab, bapineuzumab and solanezumab. Aducanumab is a recombinant antibody derived from patients with slow ...

  10. Drug

    Propiverine

    go.drugbank.com/drugs/DB12278
    Approved

    Propiverine is a widely used antimuscarinic drug with a mixed mode of action in the treatment of symptoms associated with overactive bladder (OAB) . Overactive bladder (OAB) is a chronic condition of the lower urinary tract characterized...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates